Matinas BioPharma Holdings Inc MTNB:NYSE American

Last Price$0.77AMEX Previous Close - Last Trade as of 8:00PM ET 8/18/22

Today's Change-0.01(1.70%)
Bid (Size)$0.75 (10)
Ask (Size)$0.90 (4)
Day Low / High$0.75 - 0.80
Volume258.7 K

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/18/2022


Matinas BioPharma Holdings Inc ( NYSE MKT LLC )

Price: $0.77
Change: -0.01 (1.70%)
Volume: 258.7 K
8:00PM ET 8/18/2022

scPharmaceuticals Inc ( NASDAQ )

Price: $6.09
Change: -0.04 (0.65%)
Volume: 24.7 K
4:00PM ET 8/18/2022

Ardelyx Inc ( NASDAQ )

Price: $1.06
Change: -0.02 (1.85%)
Volume: 43.00
4:00PM ET 8/18/2022

Fennec Pharmaceuticals Inc ( NASDAQ )

Price: $6.46
Change: -0.19 (2.86%)
Volume: 43.4 K
3:59PM ET 8/18/2022

Assertio Holdings Inc ( NASDAQ )

Price: $3.57
Change: +0.11 (3.18%)
Volume: 253.00
4:00PM ET 8/18/2022

Read more news Recent News

Matinas BioPharma Says European Medicines Agency Recommends MAT2203 for Designation of Cryptococcosis Treatment
7:01AM ET 7/25/2022 MT Newswires

Matinas BioPharma Holdings (MTNB) said Monday that the European Medicines Agency has recommended its cryptococcosis therapeutic candidate, MAT2203, for...

Sector Update: Health Care
3:51PM ET 4/11/2022 MT Newswires

Health care stocks were mostly lower this afternoon, with the NYSE Health Care Index sinking 1.6% while the SPDR Health Care Select Sector ETF (XLV) was...

Sector Update: Health Care Stocks Decline Premarket Monday
9:17AM ET 4/11/2022 MT Newswires

Health care stocks were declining premarket Monday. The Health Care SPDR (XLV) was down 0.22% and the iShares NASDAQ Biotechnology Index (IBB) was recently...

BioNTech, Matinas BioPharma Sign Exclusive Research Deal on Lipid Nanocrystal Technology
7:21AM ET 4/11/2022 MT Newswires

BioNTech SE (BNTX) and Matinas BioPharma Holdings, Inc. (MTNB) said Monday that they have signed an exclusive research agreement to evaluate the...

Company Profile

Business DescriptionMatinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The firm's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers a broad-spectrum fungicidal agent, amphotericin B, and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded by Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ. View company web site for more details
Address1545 Route 206 South
Bedminster, New Jersey 07921-9999
Number of Employees15
Recent SEC Filing08/11/202210-Q
President, Chief Executive Officer & DirectorJerome D. Jabbour
Chief Financial OfficerKeith A. Kucinski
Chief Scientific Officer & Senior Vice PresidentRaphael J. Mannino
Chief Medical OfficerJames J. Ferguson

Company Highlights

Price Open$0.80
Previous Close$0.77
52 Week Range$0.49 - 1.61
Market Capitalization$167.0 M
Shares Outstanding216.9 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement11/14/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.12
Beta vs. S&P 500N/A
Revenue$119.8 K
Net Profit Margin-2,394.06%
Return on Equity-50.55%

Analyst Ratings as of 10/13/2021

Consensus RecommendationConsensus Icon
Powered by Factset